<DOC>
	<DOCNO>NCT01032304</DOCNO>
	<brief_summary>The aim study evaluate effect erdosteine , compare placebo , exacerbation rate 12-month treatment period patient moderate-to-severe COPD . Moreover , effect erdosteine pulmonary function parameter , clinical symptom quality life , long-term safety drug assess .</brief_summary>
	<brief_title>The Efficacy Safety Erdosteine Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Erdosteine</mesh_term>
	<criteria>COPD stage IIIII GOLD At least 2 exacerbation previous 212 month Acute exacerbation 2 month prior enrolment Diagnosis asthma and/or relevant lung disease COPD stage IV Unstable concurrent disease</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>